Researchers use tiny 3D spheres to combat tuberculosis

Image
ANI New Delhi [India]
Last Updated : Feb 08 2017 | 4:42 AM IST

Researchers at the University of Southampton have developed a new 3D system to study human infection in the laboratory.

Funded by the Medical Research Council, it is published in mBio and a similar study in eLife.

The team, which includes infection researchers, engineers and bioinformaticians in Southampton and at University College London, has used an electrostatic encapsulation technique to make tiny 3D spheres within which human cells are infected with tuberculosis (TB) bacteria to generate conditions that more closely reflect events in patients.

The model allows the researchers to further investigate what happens in a human body when TB develops, with a long term aim of identifying new antibiotic treatments and vaccines.

Professor Paul Elkington, who leads the Southampton TB research group, commented: "We believe this is a really exciting development for the field of tuberculosis research. The 3D sphere can be created with a collagen matrix so it is more like a human lung. This produces an environment which allows particular antibiotics that are important in treating patients, to kill the infection, which they cannot do in other 2D model systems. This system will help us speed up the process of finding treatments and vaccines for human tuberculosis, an infection that kills 1.8 million people per year."

Additionally the 3D spheres are able to prolong experiments for up to three weeks, more than four times longer than standard 2D model systems. This gives researchers more information about how the infection develops and the effect of different interventions over time.

The next phase of the research will be in collaboration with the African Health Research Institute in Durban, in a project being funded by an MRC Global Challenges Research Fund Foundation Award worth £350,000.

Durban has a very high incidence of TB and ideal laboratory infrastructure to introduce the 3D model to study cells from patients at high risk of tuberculosis.

Professor Elkington added: "We are delighted to extend our research and have the opportunity to combine diverse expertise to develop an advanced laboratory system that can be applied to a wide range on infections, especially the infections that are prevalent in resource-poor countries. We will use our 3D model to integrate engineering and biological approaches with clinical specimens to create an entirely new system of studying infection."

Dr Al Leslie, of the Africa Health Research Institute, said: "There is a huge amount to be gained from infectious disease biologists and engineers working together, as they push each other out of their comfort zones and force a new perspective on the problem being tackled. This grant is the start of what we hope to be a long-term collaboration that will bring real innovation to our TB research programmes and speed up the pace of discovery to fight this deadly epidemic.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Feb 08 2017 | 4:28 AM IST

Next Story